Replies to post #2829 on Revance Therapeutics Inc (RVNC)

[DewDiligence]

Wouldn’t lack of insurance coverage seriously inhibit off label use in any therapeutic indication?

Yes—but maybe not to as large a degree as some investors think. If the annualized cost of properly treating a CD patient is less using Daxxify than using Botox—which will likely be true given what RVNC has said about pricing—third-party payers will have an incentive to reimburse for Daxxify treatments.